Dr. Sulaiman Al Habib Medical Group, a leading healthcare provider in the Middle East, announced a 3.72% increase in its net profit for 2025, reaching SAR 2.4 billion. This strong financial performance, compared to a net profit of SAR 2.31 billion in 2024, reflects the Group's continued sustainable growth and its ability to adapt to market changes.
Reasons for growth and strategic expansions
According to a statement published by the company on the Saudi Stock Exchange (Tadawul), this increase is primarily attributed to revenue growth. The group indicated that its new strategic expansion projects are still in the gradual acceleration phase, meaning they have not yet reached full operational capacity. Fixed operating costs associated with these expansions have temporarily impacted profit margins, and these margins are expected to improve as the new projects reach optimal operational maturity, which will strengthen future financial performance.
General context and importance of the health sector in the Kingdom
Founded in 1995, Dr. Sulaiman Al Habib Medical Group has grown to become one of the largest private healthcare providers in Saudi Arabia and the Gulf region, operating a vast network of hospitals, medical centers, and pharmacies. This growth comes amidst the significant transformations underway in the Saudi healthcare sector, a key pillar of Vision 2030. The Vision aims to enhance the private sector's role in delivering high-quality healthcare services, increase hospital capacity, and localize advanced medical technologies—all of which directly benefit leading companies like Al Habib Medical Group, which capitalize on increased demand and a stimulating investment environment.
Economic impact and future prospects
The strong financial performance of Al Habib Medical Group reflects investor confidence in the Saudi healthcare sector and its ability to deliver sustainable returns. Domestically, the group's success contributes to strengthening the non-oil economy and creating specialized employment opportunities. Regionally, these results solidify the group's position as a leading model in the management and operation of major medical facilities. Internationally, the continued growth of Saudi companies of this scale attracts further foreign investment to the Saudi market and enhances the Kingdom's reputation as a promising investment destination in vital and future-oriented sectors.
Distribution of cash dividends to shareholders
To further strengthen shareholder confidence, the Group’s Board of Directors, at its meeting on February 14, 2026, resolved to recommend a cash dividend for the fourth quarter of 2025 totaling SAR 458.5 million. The dividend will be distributed across 350 million eligible shares, at a rate of SAR 1.31 per share, representing a distribution of 13.3% of the share’s par value. The record date for dividend entitlement for shareholders is set for the close of trading on February 19, 2026, with distribution commencing on March 9, 2026.
